SCHEMBL1773702

SCHEMBL1773702

NC(=O)c1ccc(B(O)O)c(N2CCOCC2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
HTT P42858 2/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
GPR55 Q9Y2T6 1/20 0.40
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
PRKDC P78527 1/20 0.39
PARP1 P09874 1/20 0.38
MAP2 P11137 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TYK2 P29597 1/20 0.36
HPGD P15428 1/20 0.36
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040295 0.87 NPC1 (0.43) MAPTHTTPOLBPARP1MKNK1
SCHEMBL22362588 0.72 ALDH1A1 (0.44) MAPTHTTPOLBAURKARPS6KB1
SCHEMBL828076 0.72 ALDH1A1 (0.48) MAPTHTTPOLBAURKARPS6KB1
SCHEMBL2231719 0.70 AURKA (0.50) MAPTHTTPOLBGPR55AURKA
SCHEMBL17979907 0.70 ALDH1A1 (0.58) MAPTHTTPOLBTSHRAURKA
SCHEMBL28496853 0.68 AURKA (0.51) TSHRAURKARPS6KB1PARP1KDM4E
SCHEMBL4351617 0.67 PRKDC (0.59) MAPTHTTPRKDCPARP1MKNK1
SCHEMBL3230406 0.67 PRKDC (0.58) MAPTHTTPOLBPRKDCPARP1
SCHEMBL7449213 0.67 AKR1C3 (0.56) MAPTHTTTSHRPRKDCMAP2
SCHEMBL827977 0.67 ALDH1A1 (0.47) MAPTHTTPOLBAURKARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC MAPT 4842/4885HTT 3539/4885POLB 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.